Drug recall D-0105-2021
Product
DOXOrubicin Hydrochloride Injection, USP, 10 mg / 5 mL (2 mg / mL), 5 mL fill in a 6 mL vial, Single Dose Vial, Rx only, Sterile, Fresenius Kabi, Lake Zurich, IL 60047. NDC: 63323-883-05
Reason for recall
Cross Contamination with Other Products: trace amounts of octreotide found during testing
Lots and codes
Batch: 6120525, exp 11/2020
Recall details
- Recalling firm
- Fresenius Kabi USA, LLC, Lake Zurich, IL
- Quantity
- 16,986 vials
- Distribution
- Nationwide USA and Puerto Rico
- Type
- Voluntary: Firm initiated
- Recall initiated
- November 17, 2020
- Terminated
- August 25, 2022
Related products
- Doxorubicin Hydrochloride – drug information
- NDC 63323-101 Doxorubicin Hydrochloride · Doxorubicin Hydrochloride 2 mg/mL · Fresenius Kabi USA, LLC
- NDC 63323-883 Doxorubicin Hydrochloride · Doxorubicin Hydrochloride 2 mg/mL · Fresenius Kabi USA, LLC